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Wild-type p53 and TGF-β are key tumour suppressors which regulate an array of cellular responses. TGF-β signals in part via
the Smad signal transduction pathway. Wild-type p53 and Smads physically interact and coordinately induce transcription of
a number of key tumour suppressive genes. Conversely mutant p53 generally subverts tumour suppressive TGF-β responses,
diminishing transcriptional activation of key TGF-β target genes. Mutant p53 can also interact with Smads and this enables
complex formation with the p53 family member p63 and blocks p63-mediated activation of metastasis suppressing genes to
promote tumour progression. p53 and Smad function may also overlap during miRNA biogenesis as they can interact with the
same components of the Drosha miRNA processing complex to promote maturation of specific subsets of miRNAs. This paper
investigates the crosstalk between p53 and TGF-β signalling and the potential roles this plays in cancer biology.
1. Introduction
Transforming growth factor beta (TGF-β) is a pleiotropic
cytokine responsible for the regulation of nearly every
human cell type. Under normal conditions, TGF-β functions
in a context specific manner to maintain tissue homeostasis
largely via transcriptional regulation of genes involved in
proliferation, cell survival and cytostasis, diﬀerentiation, cell
motility and the cellular microenvironment [1–8]. Unsur-
prisingly, the function of this habitual tumour suppressor is
commonly found to be perturbed in cancer cells via receptor
and pathway component mutations and oncogene crosstalk
[1, 4, 9]. Paradoxically, TGF-β can also act as a tumour pro-
moter as tumourigenesis progresses [1, 3, 4, 10–12].
TGF-β signalling is mediated through binding of a TGF-
β isoform (TGF-β1, 2 or 3) to a transmembrane heterote-
trameric complex of the serine/threonine kinase receptors
TβRII and TβRI [13–15]. Activation of the TGF-β receptors
results in the downstream phosphorylation of transcription
factors Smad2 and 3, which subsequently dissociate from
the receptor before binding their constitutive co-smad,
Smad4 (Figure 1) [1, 5, 16–18]. The active Smad complex
accumulates in the nucleus where it functions to regulate
transcription of a myriad of target genes including p21
and proapoptotic BH3-only members of the BCL2 family
(Figure 1) [6, 8, 19, 20].
As well as the activation of the Smad dependent signalling
pathway, TGF-β can also regulate non-Smad pathways such
as the JNK/p38, Ras-ERK, PI3K/Akt, and RhoA pathways
[2, 21, 22]. These pathways can then act to regulate many
cellular proteins including Smad interacting coactivators and
corepressors and thereby contribute to the context specificity
of TGF-β signalling (Figure 1) [2]. Regulation of biological
processes by TGF-β signalling is consequently brought to
fruition by integration of these signalling cascades with other
physiological pathways operating in the target cell.
Renowned as the “Guardian of the Genome” p53 has
a critical role in maintaining the genetic integrity of pro-
liferating cells thereby preventing malignant transformation
[23–25]. p53 acts primarily as a transcription factor [26]. In
response to stress signals for example, genotoxic stress, DNA
damage, oncogene activation, and hypoxia, p53 is stabilised
resulting in its accumulation and subsequent recruitment to
p53 binding sites in chromatin [23, 27–29]. Once chromatin
bound, p53 promotes transcriptional activation of numerous
target genes responsible for apoptosis for example, BH3-only
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family members and cytostasis for example, p21, [30–33].
More recently p53 has been found to have a much broader
range of functions stimulating DNA repair, cell adhesion, cell
motility, membrane functioning, and metabolism [23, 34].
With its central role in tumour suppression, p53 is the
most commonly mutated gene in cancer with over 50% of
tumours expressing a mutant variant [35, 36]. Mutations are
particularly prominent in the central DNA binding domain
with 74% occurring here, 30% of which occur at six hotspot
codons [35]. Mutation of p53 can result in a gain of function
acting to promote tumourigenesis [23, 36, 37]. Additionally
once mutated p53 may have a dominant negative eﬀect
over its wild-type counterpart acting to induce chromosomal
instability, a feature of tumour progression, and suppress
genes involved in cell cycle control, apoptosis, and DNA
repair pathways [36, 38, 39].
2. TGF-β and Wild-Type p53
Pathway Convergence
Under normal phenotypic conditions, both TGF-β and
activated p53 act as gene-specific transcription factors to
each regulate a multitude of gene targets producing tumour-
suppressive eﬀects. Due to the broad ranging nature of these
proteins, overlap of cellular functions occurs in the regula-
tion of cytostasis, apoptosis, and autophagy indicating sev-
eral potential points of convergence. The initial link between
the wild-type p53 and TGF-β pathway was proposed in
1991 by Wyllie et al. Inactivation of wild-type p53 by the
SV40 virus resulted in loss of response to TGF-β treatment
implying that loss of p53 may prelude resistance to the
tumour-suppressive eﬀects of TGF-β [55]. More recently
several studies have demonstrated the convergence of p53
and Smad signalling pathways.
2.1. Unearthing the Interaction. p53 has been identified as a
gene-specific partner for Smads important for the formation
and stabilisation of Smad-DNA complexes. The suggestion of
such a partnership was first revealed by functional assays in
Xenopus embryos searching for modulators of TGF-β family
signalling regulated processes during early development [47,
56]. In both screens, p53 was found to regulate development
and that this activity required Smad proteins operating
through regulation of specific target genes such as Mix2
[47, 56]. Upon TGF-β/Activin, signalling FAST-1 forms a
complex with Smads at the Mix2 promoter thereby facili-
tating gene transcription [57]. Using the Xenopus embryo
model system, Cordenonsi et al. demonstrated that in the
presence of a p53 isoform (p53AS) along with FAST-1, TGF-
β induces a robust increase in the transcription of Mix2
and importantly this eﬀect was diminished upon p53 knock
down [47]. In the same study, Cordenonsi et al. used the
mammalian HEK293T cell line to further elucidate the
mechanism of this p53-Smad interaction. Both Smad2 and
3, but not Smad4, were found to directly bind immobilised
wild-type p53 and p73 [47]. Specifically, binding occurs
through the phosphorylated N-terminal domain of activated
p53 and the N-terminal MH1 domain of Smad2/3 with the
C-terminal MH2 domain free to interact with Smad4 [47].
Coupling of these proteins is dependent upon the phospho-
rylation of p53 at Serine 6 and 9 of the N-terminal trans-
activational domain. Phosphorylation of these residues typ-
ically occurs in response to DNA damage. However, the
Ras/MAPK cascade acting via casein kinase 1 (CK1) δ and
ε can also promote this phosphorylation as demonstrated
in mammalian H1299 cells [46]. Crucially, inhibition of the
Ras/MAPK eﬀector MEK abrogated p53 phosphorylation
and subsequently diminished induction of key TGF-β cyto-
static genes p21 and p15 thus indicating that p53 serves to
integrate crosstalk between Ras/MAPK and TGF-β signalling
[46]. This interaction of p53 with Smads 2 and 3 occurs in a
TGF-β dependent fashion [47]. However, to induce a robust
increase in TGF-β mediated gene transcription p53 must
contact its own cognate site within the gene promoter [46–
48]. Deletion or point mutation of the DNA binding domain
of p53 blocks its biological activity as demonstrated in
Xenopus assays and thereby impedes complex formation of
the protein with Smads [47, 48, 56]. Thus Smad2/3may act as
a bridge between p53, bound at the p53 binding-element and
the Smad complex, bound at the TGF-β responsive-element,
allowing synergistic activation of transcription (Figure 2)
[46–48].
Synergism between p53 and TGF-β occurs only with a
subset of TGF-β target genes with p53 presence having no
eﬀect on the inducibility of others for example, TIEG-1/2
[47]. In spite of this, bioinformatic screening of 800 TGF-
β target regulatory sequences versus a genomic database
of putative p53 DNA-binding sites revealed in excess of
200 genes could be potentially coregulated [48]. However,
clustering analysis of these genes predicted only growth in-
hibitory and extracellular matrix functions to be under joint
regulatory control [48]. In support of this, TGF-β target
genes such as p21 and p15 (growth inhibition), PAI-1 and
MMP2 (extracellular matrix) require wild-type p53 for full
activation [46, 47]. Interestingly, in the context of cytostasis
wild-type p63 can compensate for p53 mutation having a
functional overlap in regulating at least the p21 gene which
is required for cell cycle arrest [47]. A prime example is
the TGF-β responsive HaCaT cell line, which is p53 mutant
but expresses high levels of p63. Following p63 directed
siRNA p21 induction by TGF-β was reduced [47]. However
more recently, mutant p53 and TGF-β have been found to
complex and induce TGF-β-induced metastasis suggesting
coregulation of additional cell responses may also occur [53]
(see below).
2.2. Smad and Wild-Type p53 miRNA Crossover. MicroRNAs
(miRNAs) are small, noncoding RNAs that regulate protein
expression by inhibiting translation and increasing degrada-
tion of mRNA [58–60]. Primary (pri-) miRNA is transcribed
as a long transcript, which folds back to form a hairpin
structure [61]. Inside the nucleus DROSHA processes pri-
miRNAs cleaving the 5′ Cap and 3′ Poly (A) tail to form
precursor (pre-) miRNAs which are then transported to the
cytoplasm via exportin 5 where cleavage by DICER produces
mature miRNAs [58, 59, 62]. Once matured miRNAs are
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Figure 1: Canonical and Noncanonical TGF-β signalling. Initiation of the TGF-β signalling cascade occurs via binding of active TGF-β
ligand to the TGF-β type 2 receptor (TGF-βRII) [1, 5]. Once bound TGF-βRII is then able to activate its partner the TGF-β type 1 (TGF-
βRI)/ALK5 receptor via phosphorylation [1, 14]. Phosphorylation of TGF-βRI results in a conformational change by which the kinase
repressive N-terminal GS domain is flipped to act as a docking site for Receptor Smad (R-smad) proteins for example, Smad2 and 3
and in turn facilitates signal transduction by activation of the catalytic kinase domain [1, 16]. TGF-βRI phosphorylates Smad2 and 3,
which associate with their co-smad Smad4 to form the active Smad complex, which accumulates in the nucleus via nucleoporin-mediated
transport [5, 40]. Phosphorylation acts to inhibit the constant nucleocytoplasmic recycling of Smads resulting in nuclear accumulation [41].
Smads associate with DNA via binding at target gene DNA-Smad Binding Element’s (DNA-SBE), with a optimal conserved sequence of
5′-CAGAC-3′ [17, 42]. However, the Smad complex has only relatively weak DNA-binding aﬃnity. Thus, association with numerous DNA-
binding transcription factors for example, Zinc-fingers, homeobox and bHLH families, coactivators (e.g., CBP-300), corepressors (e.g.,
RBL1) and chromatin remodeling factors (e.g., Histone Deacetylase (HDAC)) allows the complex to achieve specific cell responses
[17, 42, 43]. In addition activated TGF-βRI can also activate multiple noncanonical pathways. These Smad independent pathways can
function autonomously to achieve a wide array of cellular responses in a transcription-independent manner [21]. In addition activation
of the JNK, ERK, and CDK8/9 pathways regulate Smad linker phosphorylation to regulate Smad activity [22, 44].
incorporated into the RNA-Induced Silencing Complex
(RISC), which positions the miRNA with its target mRNA at
the 3′UTR to mediate inhibition [58–60, 63].
The downregulation of mature miRNAs either at the
genomic level, by epigenetic modifications or by impaired
biogenesis is observed in human malignancies resulting in
the promotion of cellular transformation and tumourigen-
esis [64–66]. Extracellular signals can influence the matura-
tion of specific miRNAs, for example TGF-β and p53 have
been found to positively regulate their biogenesis [49, 50].
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Figure 2: Coregulation of gene transcription by p53 and Smad complexes. In the absence of cellular stress p53 is maintained at a low
concentration by its negative regulator MDM2 [27, 28, 45]. MDM2 acts to poly-ubiquitinate p53, which targets the tumour suppressor to the
proteasome for degradation. In response to DNA damage p53 is phosphorylated at defined Ser/Thr residues resulting in its stabilisation and
dissociation fromMDM2 [29]. In addition signalling via the Ras/MAPK pathway CK1δ/ε can also result in the activating phosphorylation of
p53 [46]. Activated wild-type p53 can act synergistically with Smads to increase the transcription of a subset of genes for example, p21, PAI-1
[46, 47]. The model depicted was originally proposed by Piccolo and colleagues and elegantly demonstrates how p53 and Smads may interact
[46–48]. For synergism to occur, the target gene must possess both a DNA-SBE and a p53 response element (RE) to which the activated Smad
complex and p53 bind respectively. Once bound at their respective sequences a direct interaction between Smads and p53may occur in which
the N-terminal MH1 domain of Smads2/3 binds the N-terminal transactivational domain (TA) of p53 [46–48]. Association within the gene
promoter acts to maximally induce gene transcription.
Such positive regulation on biogenesis may act in a tumour
suppressive manner for example, TGF-β and p53 induce
miR-215, which acts to induce growth arrest and decrease cell
proliferation [51, 67, 68]. Conversely, a positive regulation on
biogenesis may also lead to tumour progression for example,
TGF-β increases miR-21 maturation [51], which can act to
inhibit PTEN and Sprouty 1 key negative regulators of the
Akt and Ras/MAPK pathways allowing their aberrant activity
[69, 70].
Both p53 and TGF-β can act transcriptionally to regulate
the expression of miRNAs by binding at their response
elements within target promoters. It is plausible that p53 and
TGF-β may converge via the p53-Smad interaction as earlier
described to synergistically regulate miRNA transcription.
However, whether such an interaction at miRNA promoters
does in fact occur is yet to be described.
In response to TGF-β signalling miRNA microarray
profiling of PASMCs revealed mature levels of 20 miRNAs,
including miR-21, that were induced in excess of 1.6-fold
[51]. Of these miRNAs analysis by Davis et al. revealed 85%
contained a conserved stem sequence (CAGAC) homologous
to that of the SMAD-binding element present in DNA
(Figure 3) [51]. This RNA Smad-binding element (R-SBE)
was absent in non-TGF-β-induced miRNA’s [51]. In C3H
10T1/2 cells mutation of more than 2 bp in the R-SBE
sequence abolished the production of these mature miRNAs
revealing that Smads must associate with these miRNAs di-
rectly for upregulation to occur [51].
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Figure 3: Potential overlapping functions of TGF-β and p53 in microRNA processing. Smads and p53 act to increase the posttranscriptional
maturation of a subset of miRNAs via direct binding of the DROSHA-associated helicase p68 [49–52]. These miRNAs have crucial roles in
tumour suppression acting in cytostasis and DNA repair. Interestingly pro-survival miRNAs are also upregulated indicating a possible
mechanism for protumourigenesis by inhibition of key tumour suppressors. However, upregulation of these prosurvival miRNAs may also
facilitate the induction of senescence, protecting cells from cell death induced by tumour suppressor genes. In addition to acting as a mo-
lecular tag to direct DROSHA activity binding of Smads and p53 may act to promote p68 helicase activity, which could act to induce
conformational changes in pri-miRNA structure making it accessible for DROSHA cleavage. As proposed by Davis et al. competition may
occur between Smads and p53 for binding to p68 upon which binding of one protein results in the inhibition of p68 association with other
[51]. Binding of Smads to microRNAs is mediated by association with CAGAC Smad DNA-binding-like elements (SBEs) and a similar p53
response-element- (RE) mediated mechanism may also occur for p53. Potential RE and SBE sequence overlap may also occur adding a
potential further layer of cross-regulation.
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Posttranscriptionally Davis et al. defined how Smad’s
enhance miRNA maturation. Following TGF-β treatment of
PASMC cells the induction of both pre- and mature miR-
21 was observed, however, no change in expression of
pri-miR-21 was seen indicating TGF-β components must
act posttranscriptionally with DROSHA [49, 51]. Use of
recombinant GST-Smad fusion proteins demonstrated that
the MH1 domain of Smads is responsible for binding of the
R-SBE in miRNAs with this domain binding and pulling
down 18-fold more pri-miR-21 than GST, whereas the
MH2 domain did not bind at all [51]. The association of
Smads with miRNAs is unable to facilitate their maturation,
instead Smad binding is proposed to act as a molecular
tag-promoting interactions with the processing machinery
[51]. Both Davis et al. and Warner et al. reported that the
MH2 domain of TGF-β Smad2/3 (but not Smad4) interacts
with the RNA helicase p68 (Figure 3) [49, 52]. p68 is part
of the DROSHA multicomponent processing complex and
may function to recognise and bind specific pri-miRNA
structures and thus localise DROSHA for cleavage [71].
Further investigation in PASMCs by Davis et al. revealed
that siRNA of p68 inhibited the TGF-β-mediated induction
of pre- and mature miR-21 thereby demonstrating it’s
essential role in potentiating DROSHA processing [49]. The
enhancement in miRNA maturation may facilitate TGF-β
tumour-promoting functions. For example miR-21 is highly
expressed in several breast tumour cell lines including,
MCF7 and MDA-MB-468 cells where it acts to suppress
the apoptotic tumour suppressor programmed cell death 4
(PDCD4) [49].
In response to DNA damage activated wild-type p53 can
transcriptionally upregulate miRNAs via direct binding at
target promoters for example, miR-34. In addition activated
p53 can also act post-transcriptionally to promote the mat-
uration of a subset of miRNAs important in the regulation
of cell cycle and proliferative genes for example, K-Ras and
CDK6 [50]. Notably these miRNAs are distinct from those
induced by TGF-β having no R-SBE. Suzuki et al. determined
that like the Smads p53 interacts with the RNA helicases
p68 and p72 to facilitate DROSHA processing (Figure 3)
[50]. Mutation of p53 also results in decreased miRNA
maturation, however, as mutant p53 still associates with
p68 suppression must occur in a transcription-dependent
manner [50].
As both p53 and Smads can interact with the same
components of the Drosha complex it is possible that activa-
tion of these transcription factors may result in competition
for Drosha complex components and may therefore cross-
regulate each other’s responses. Indeed Davis et al. noted that
maturation of Smad-regulated miRNAs is enhanced in cells
with loss of p53 function, for example the mutant p53 cell
line MDA-MB-468 versus the wild-type p53 PASMCs [51].
3. Inhibition of TGF-β Tumour Suppressor
Function by p53 Mutation
3.1. Transcriptional Activation of TGF-β Target Genes. p53
mutants have been found to aﬀect numerous stages of
the TGF-β pathway; by repressing of the TGF-βRII gene,
delaying or reducing phosphorylation of Smad2 by TGF-
βRI, and interfering with Smad2/3 and Smad4 association
and inhibiting Smad translocation to the nucleus [72]. By
aﬀecting the TGF-β pathway Smad-dependent transcription
of target genes is ablated and thus TGF-β mediated cellular
responses. In addition p53 mutation can result in a loss
of DNA-binding capacity thereby inhibiting coupling with
Smad’s at gene-specific promoters for example, Mix2, PAI-
1, and p21 and thus transcriptional induction of these
genes is diminished [46, 72]. p21, a cyclin-dependent kinase
inhibitor, acts to induce a functional G1 arrest via the
inhibition of downstream cell cycle regulators CDK4/Cyclin
D1 and CDK2/Cyclin E. Inhibition results in the hypophos-
phorylation of the retinoblastoma (Rb) protein preventing
its release from E2F, a key transcription factor for DNA
replication and thus blocking G1 to S phase progression.
Plasminogen activator inhibitor 1 (PAI-1) acts to inhibit
both the degradation of collagen and the catalytic activation
of matrix metalloproteinases (MMP) 1 and 10 [73]. When
active, these MMPs play a crucial role in the invasion of
malignant cells across the basal lamina. The degradation
of collagen also mediates this invasion as well as inva-
sion into local blood vessels allowing cells to metastasise.
Consequently diminished activation of these genes may aid
tumourigenesis inducing limitless replicative potential from
a failure to growth arrest by p21 and through MMP activity
tissue invasion and metastasis both key hallmarks of cancer
[74].
Inactivation of p53 results in aberrant behaviour of
cancer cells and may therefore represent a mechanism by
which loss of TGF-β tumour suppression occurs [75]. In
support Cordenonsi et al. found that reintroduction of the
wild-type p53 isoform p53AS in conjunction with Smad2
induced a TGF-β-mediated cytostatic response within the
normally unresponsive p53 null SAOS-2 cell line [47].
3.2. Metastasis. Recently Adorno et al. demonstrated that the
mutational status of p53 determines the nature of the cellular
response to TGF-β. Introduction of wild-type p53 into p53
null H1299 cells resulted in a TGF-β-induced growth arrest
via p21 [53]. In contrast reconstitution with mutant p53
caused cells to change from an epithelial to mesenchymal
morphology, enabling a promigratory TGF-β response [53].
Under normal conditions metastasis is inhibited by the
p53 family member p63 which acts to transcriptionally
upregulate key metastatic suppressor genes for example,
Sharp-1 and Cyclin G2 [53]. In conjunction with Smads
mutant p53 can usurp p63 functioning via ternary complex
formation. For example in metastatic D3S2 carcinoma cells,
TGF-β treatment resulted in complex formation of nearly
all the p63 with mutant p53 thereby facilitating a TGF-β
metastatic response. Formation of this complex was found
to be dependent on Smads becoming undetectable post-
transfection of Smad2/3 siRNA in HaCaT cells. To determine
the structural association of Smads in this complex GST-
pull down experiments were carried out using immobilised
GST-Smad3 and structural isoforms of p63 resulting in the
Journal of Signal Transduction 7
Smad2/3
???
Mutant p53
Ternary 
complex
Sharp-1
Cyclin G2
other?
Sharp-1
Cyclin G2
other?
Metastasis
Metastasis
Dissociation of p63 upon 
ternary complex formation
p63
(a)
Smad2/3
N
N
N
TA R175H OD C
C
C
Mutant p53
MH1
MH2
Alpha DBD OD
P
p63
(b)
Figure 4: Regulation of metastasis by mutant p53 and Smads. (a) p63 has a crucial role in the transcriptional activation of genes which
function in the inhibition of metastasis. Mutant p53 can act to inhibit the anti-metastatic functioning of p63 but is dependent upon the
formation of a ternary complex with Smads2/3 as described below [53]. Formation of a ternary complex inhibits the binding of p63 to the
DNA at target gene promoters thereby inhibiting transcription of these key antimetastatic genes and subsequently increased metastasis of
malignant cells is observed [53]. In addition mutant p53 can promote invasion and metastasis independently. For example mutant p53 can
suppress p63 in the context of integrin recycling [54]. It is yet unknown whether Smads are involved for these other routes of induction.
(b) Mutant p53 is able to inhibit p63 activity by the formation of a ternary complex. Formation of this complex is dependent on receptor
Smad2/3 acting as a molecular bridge between the proteins. The C-terminal MH1 domain of Smads2/3 binds the transactivational (TA)
domain at the N-terminus of mutant p53 [53]. The N-terminal MH2 domain binds at the C-terminal alpha domain of p63 [53]. Association
of p63 in this complex inhibits its capacity to bind DNA thus blocking transcriptional functions of the protein.
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identification of two Smad interaction sites within p63 at
the transactivational and alpha domains [38]. Importantly
the vast majority of p63 is expressed as the ΔNp63 isoform,
which lacks an N-terminal transactivation domain [38]. As
a result Adorno et al. hypothesised a structure in which R-
Smads acting as a bridge between the C-terminal alpha
domain of p63 and the N-terminal domain of p53 via respec-
tive binding of Smad MH2 and MH1 domains (Figure 4)
[53].
Similarly increased invasion is observed in the context
of integrin recycling in which mutant p53 expression again
inhibits p63 functioning. Here inhibition of p63 promotes
the association of Rab-coupling protein with α5β1 integrin
which acts to chaperone the integrin to the plasma mem-
brane where it then acts to promote tumour cell motility
[54]. There is no evidence that these processes are influenced
by TGF-β signalling and Smad interactions but this warrants
further investigation.
3.3. miRNA Biogenesis. In cells harbouring mutant p53 TGF-
β stimulation results in greater induction of TGF-β-regulated
miRNAs [51]. Davis et al. proposed that Smads and p53
might directly compete for p68 binding and hence loss of
p53/p68 interaction may release more p68 for Smad-directed
miRNA maturation (Figure 3). In addition to this proposed
mechanism of p53/Smad crosstalk in miRNA biogenesis, it
is also possible that competition between p53 and Smad
complexes for direct RNA binding in the Pri-miRNA seed
sequence may occur. Smads regulate a subset of miRNAs via
interaction with the SBE consensus AGAC sequence. p53 reg-
ulates target genes via binding to the p53 REwhich consists of
2 motifs, 5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′, separated by
a ≤13 bp spacer [76]. Computational analysis has previously
revealed these binding sites to be conserved at the miR34b/c
promoters [77]. By assuming a 5′ sequence of 5′-AGAC-3′,
this motif has the potential to overlap with the core consen-
sus at Smad-binding-elements [78]. In this case, binding of
wild-type p53 at its cognate DNA may result in the displace-
ment of Smads thereby inhibiting Smad-p68 interaction or
vice versa. This intriguing possibility and the consequence
of p53 mutation on this potential crosstalk warrants future
investigation.
4. Concluding Remarks
Establishment of TGF-β-p53 pathway crossover brings new
complexity to the regulatory functioning of these proteins.
Currently TGF-β and p53 convergence has only been found
in cytostasis, extracellular matrix functioning, andmetastasis
[48, 53]. However, it will be interesting to ascertain whether
such crossover occurs in other TGF-β and p53 functions
namely apoptosis, proliferation, and autophagy and if such
responses are dependent on the presence or phenotypic
status of both proteins.
The recent study of Adorno et al. demonstrated how the
mutational status of p53 can interfere with TGF-β switching
it’s functioning from tumour suppressive to protumorigenic
[53]. In concurrence Davis et al. shows mutant p53 confers
the ability of TGF-β to promote miRNA maturation for
example, miR-21 which can act to inhibit tumour suppres-
sors such as PDCD4 [49]. Such findings suggest that mutant
p53 may potentiate tumour-promoting functions of TGF-β
thus allowing cancer cells to proliferate and invade leading to
advanced tumours.
TGF-β has been implicated in the induction of EMT in
breast cancer stem cells and plays an essential role in main-
taining the pluripotency of these stem cells [79]. In the
Adorno et al. study p63 acts to suppress TGF-β induced EMT
[53]. However, in the presence of mutant p53 formation of
the ternary complex with p63 in conjunction with Smads acts
to inhibit this p63 suppression facilitating TGF-β induced
EMT [53]. This raises the interesting question of whether
TGF-β/Smads and p53 family members may also cooperate
to regulate tumour stem cells.
Further complexities between crosstalk of p53 family
members and their multiple splice variants [80] with TGF-
β signalling pathways are likely to be unveiled in the near
future. For example in MCF10A cells expression of ΔNp63γ
results in TGF-β-dependent EMT and subsequently increases
the expression of both TGF-β and downstream Smads2/3/4
[81]. A systematic evaluation of the eﬀects of activation of
the p53 family and TGF-β signal transduction pathways in
diﬀerent biological situations is likely to shed considerable
light and add further intrigue into the crosstalk between
these fundamentally important regulators of biology.
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